Q3 2021 Investor Relations Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD TabrectaⓇ - Inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milesstone(s) Publication NCT04427072 (CINC280A2301) Non-small cell lung cancer Phase 3 90 Progression free survival (PFS) per blinded independent review committee (BIRC) using RECIST v1.1 Arm 1: 400mg of capmatinib tablets administered orally twice daily Arm 2: Docetaxel 75 mg/m2 by intravenous infusion every 21 days Previously Treated Patients With EGFR wt, ALK Negative, Locally Advanced or Metastatic (Stage IIIB/IIIC or IV) NSCLC Harboring MET Exon 14 Skipping Mutation (MET?ex14). Primary 2022 Final: 2024 TBD NCT04816214 GEOMETRY-E (CINC280L12301) Non-small cell lung cancer Phase 3 245 Run-in part: Incidence of dose limiting toxicities (DLTs) Randomized part: Progression free survival (PFS) Arm 1: Experimental: Combination of capmatinib + osimertinib (run-in part). Arm 2: Experimental: Combination of capmatinib + osimertinib (randomized part) Arm 3: Active Comparator: platinum + pemetrexed based doublet chemotherapy Adult subjects with Non-small Cell Lung cancers as second line therapy Primary: 2025 Final: 2027 TBD 114 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine

View entire presentation